Teva And Biolojic Design Announce Exclusive License Agreement For The Development Of A Therapeutic Antibody For Atopic Dermatitis And Asthma
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Biolojic Design Ltd. have entered into an exclusive license agreement to develop BD9, a novel antibody therapy for Atopic Dermatitis and Asthma. BD9 is a dual specific antibody targeting IL-13 / TSLP, designed to treat inflammatory diseases more effectively than current therapies. The agreement aligns with Teva's Pivot to Growth strategy to enhance its early-stage pipeline. Teva will have exclusive worldwide rights to develop and commercialize BD9, while Biolojic will receive an upfront payment, milestone payments, and royalties on product sales.
December 14, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva's exclusive license agreement with Biolojic for BD9 development could enhance its pipeline and address unmet needs in Atopic Dermatitis and Asthma treatment. The deal reflects Teva's commitment to innovation and strategic partnerships.
The exclusive agreement to develop BD9 is likely to be viewed positively by investors as it represents a strategic move to strengthen Teva's pipeline and address significant market needs. The potential for BD9 to outperform existing treatments could lead to increased investor confidence in Teva's growth strategy and future revenue streams, thus potentially driving the stock price up in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90